Baidu
map

CCLM:在健康的CALIPER队列中使用DiaSorin LIAISON XL测定1,25-二羟基维生素D的儿科参考区间

2018-07-17 MedSci MedSci原创

1,25-二羟基维生素D(1,25(OH)2 D)是一种生物活性维生素D代谢物,在钙和磷酸盐稳态中起着关键作用。测量1,25(OH)2 D可评估钙和磷酸盐代谢,特别是在高速生长和发育期间。尽管其非常重要,但目前尚无可靠的儿科参考区间,且可使用的参考范围也是基于成人人群或过时的方法而开发的。我们使用DiaSorin的全自动化学发光免疫测定法,对来自CALIPER队列的健康儿童和青少年建立了1,25(

1,25-二羟基维生素D1,25OH2 D)是一种生物活性维生素D代谢物,在钙和磷酸盐稳态中起着关键作用。测量1,25OH2 D可评估钙和磷酸盐代谢,特别是在高速生长和发育期间。尽管其非常重要,但目前尚无可靠的儿科参考区间,且可使用的参考范围也是基于成人人群或过时的方法而开发的。我们使用DiaSorin的全自动化学发光免疫测定法,对来自CALIPER队列的健康儿童和青少年建立了1,25OH2 D儿科参考区间。

研究人员使用DiaSorin LIAISON XL测定法分析来自健康受试者(0<19岁)的血清样品的1,25OH2 D,并建立年龄特异性参考区间。Mann-Whitney U检验用于确定季节差异。使用液相色谱串联质谱(LC-MS / MS)对合并的新生儿和婴儿样品进行定量,以确定在第一年中升高的浓度是否可归因于交叉反应的部分。

结果显示,在0<1年(77-471pmol / L)的受试者中需要三个参考区间年龄分区,同时 1年后(113-363pmol / L)下降和变窄,3年时稳定下来(108-246)皮摩尔/ L)。1,25OH2 D浓度不受季节变化或性别的影响。新生儿和婴儿样品中1,25OH2 D浓度升高可能是干扰物质影响的结果。在合并的样品中不存在3-epi-1,25-二羟基维生素D,因此不太可能是干扰部分。

本研究建立了1,25OH2 D的儿科参考区间,以改善对儿童和青少年的测试结果解释。1,25OH2 D在新生儿和婴儿的比例中升高,这可能是交叉反应部分的结果。

原始出处:

Higgins, Victoria Truong, Dorothy, Pediatric reference intervals for 1,25-dihydroxyvitamin D using the DiaSorin LIAISON XL assay in the healthy CALIPER cohort

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1662275, encodeId=3b2416622e57e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 08 02:40:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638698, encodeId=cad01638698c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 10 09:40:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913759, encodeId=c8d71913e5991, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 03 03:40:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727437, encodeId=ba351e2743798, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 01 14:40:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634940, encodeId=07e91634940cc, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Aug 17 20:40:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546902, encodeId=31cb154690240, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Jul 19 06:40:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332254, encodeId=7a2d3322549d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jul 17 16:27:45 CST 2018, time=2018-07-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1662275, encodeId=3b2416622e57e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 08 02:40:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638698, encodeId=cad01638698c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 10 09:40:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913759, encodeId=c8d71913e5991, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 03 03:40:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727437, encodeId=ba351e2743798, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 01 14:40:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634940, encodeId=07e91634940cc, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Aug 17 20:40:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546902, encodeId=31cb154690240, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Jul 19 06:40:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332254, encodeId=7a2d3322549d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jul 17 16:27:45 CST 2018, time=2018-07-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1662275, encodeId=3b2416622e57e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 08 02:40:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638698, encodeId=cad01638698c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 10 09:40:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913759, encodeId=c8d71913e5991, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 03 03:40:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727437, encodeId=ba351e2743798, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 01 14:40:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634940, encodeId=07e91634940cc, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Aug 17 20:40:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546902, encodeId=31cb154690240, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Jul 19 06:40:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332254, encodeId=7a2d3322549d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jul 17 16:27:45 CST 2018, time=2018-07-17, status=1, ipAttribution=)]
    2019-07-03 huangdf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1662275, encodeId=3b2416622e57e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 08 02:40:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638698, encodeId=cad01638698c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 10 09:40:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913759, encodeId=c8d71913e5991, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 03 03:40:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727437, encodeId=ba351e2743798, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 01 14:40:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634940, encodeId=07e91634940cc, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Aug 17 20:40:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546902, encodeId=31cb154690240, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Jul 19 06:40:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332254, encodeId=7a2d3322549d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jul 17 16:27:45 CST 2018, time=2018-07-17, status=1, ipAttribution=)]
    2019-07-01 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=1662275, encodeId=3b2416622e57e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 08 02:40:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638698, encodeId=cad01638698c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 10 09:40:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913759, encodeId=c8d71913e5991, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 03 03:40:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727437, encodeId=ba351e2743798, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 01 14:40:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634940, encodeId=07e91634940cc, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Aug 17 20:40:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546902, encodeId=31cb154690240, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Jul 19 06:40:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332254, encodeId=7a2d3322549d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jul 17 16:27:45 CST 2018, time=2018-07-17, status=1, ipAttribution=)]
    2018-08-17 膀胱癌
  6. [GetPortalCommentsPageByObjectIdResponse(id=1662275, encodeId=3b2416622e57e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 08 02:40:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638698, encodeId=cad01638698c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 10 09:40:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913759, encodeId=c8d71913e5991, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 03 03:40:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727437, encodeId=ba351e2743798, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 01 14:40:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634940, encodeId=07e91634940cc, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Aug 17 20:40:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546902, encodeId=31cb154690240, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Jul 19 06:40:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332254, encodeId=7a2d3322549d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jul 17 16:27:45 CST 2018, time=2018-07-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1662275, encodeId=3b2416622e57e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 08 02:40:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638698, encodeId=cad01638698c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 10 09:40:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913759, encodeId=c8d71913e5991, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 03 03:40:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727437, encodeId=ba351e2743798, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 01 14:40:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634940, encodeId=07e91634940cc, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Aug 17 20:40:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546902, encodeId=31cb154690240, content=<a href='/topic/show?id=ed723e350e0' target=_blank style='color:#2F92EE;'>#参考区间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37350, encryptionId=ed723e350e0, topicName=参考区间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=910c13959987, createdName=12498dabm81暂无昵称, createdTime=Thu Jul 19 06:40:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332254, encodeId=7a2d3322549d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jul 17 16:27:45 CST 2018, time=2018-07-17, status=1, ipAttribution=)]
    2018-07-17 1209e435m98(暂无昵称)

    学习了谢谢分享

    0

相关资讯

N Engl J Med:Glecaprevir-Pibrentasvir治疗HCV基因1或3型患者,可达到很好的治疗效果

采用glecaprevirp -pibrentasvir治疗无肝硬化的HCV基因1型或基因3型患者8周或12周,可达到很高的可持续病毒学应答率

J Hepatol:肝细胞特异性缺失的IL1-RI,通过阻断IL-1驱动的自体炎症,减轻了肝脏损伤

肝细胞中的IL-1R1通过IL-1驱动的细胞死亡和炎症反应,发挥关键作用

J Periodontol: 缺乏1,25-二羟基维生素D是否会加速牙槽骨吸收

维生素D对骨稳态和免疫调节至关重要。因此,我们评估在缺失编码1,25-二羟基维生素D-1α羟化酶[1α(OH)ase]的小鼠(1α(OH)ase - / - 小鼠)中1,25-二羟基维生素D(1,25(OH)2 D) )是否会导致体内牙槽骨吸收和牙周炎。

Hepatology:鞘氨醇激酶1通过下调miR-19b-3p的表达来增加CCR2的表达,进而促进肝纤维化

在肝纤维化过程中,SphK1对KCs和HSCs的激活具有明显不同的作用。在机制上,在KCs中SphK1介导CCL2的分泌;在HSC中,SphK1通过下调miR-19b-3p的表达来增加CCR2的表达。

Oncotarget:Beclin 1和LC3可作为预测转移性结直肠癌的生物标志物

自噬是一种高度保守的代谢过程,表现为细胞对不正常的或不需要的细胞成分的“自食”。自噬在癌症转移中扮演著着重要的角色,而转移性疾病是结直肠癌导致相关死亡的主要原因。

J Biol Chem:上海药物所等胰高血糖素样肽 - 1 受体结构与功能研究获进展

中国科学院上海药物研究所和澳大利亚莫纳什大学药学研究所两个团队关于胰高血糖素样肽 - 1 受体偏向激活的合作研究成果以 Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism 为题发表在 The Journal of Biological Chemist

Baidu
map
Baidu
map
Baidu
map